Summary Local extension prevents curative resection in more than two-thirds of gastric cancer patients. Unfortunately, resectability is one of the main prognostic factors in these patients, and survival is longer when tumours are completely removed. Preoperative chemotherapy is an attractive concept for obtaining curative resection. Thirty-two locally advanced unresectable gastric cancer patients were enrolled in five Italian Group for the Study of Digestive Tract Cancer (GISCAD) centres. For 16 patients, surgical unresectability was based on computerized tomography scan evaluation of tumour size (four patients) and invasion of adjacent structures (12 patients), whereas in another 16 patients locally advanced disease was confirmed by laparotomy. They received weekly administration of cisplatin 40 mg m-2. 5-fluorouracil 500 mg in-2, epidoxorbicin 35 mg m-2, 6S-stereoisomer of leucovorin 250 mg rT2 and glutathione 1.5 g m-2. From the day after to the day before each chemotherapy administration, filgrastim was administered by subcutaneous injection at a dose of 5 lig kg-'. One cycle of therapy consisted of eight weekty treatments. Fifteen of 32 patients (470o) responded to chemotherapy, whereas 13 (410%) had stable disease and four (12°h) progressed on therapy. Of the 15 responding patients, 13 were completely resected after chemotherapy and two of them had a complete pathological response. Two clinically responding patients were found unresectable at operation because of perntoneal seeding. At a median follow-up from the start of treatment of 24 months (range 11-39 months), 10 of 13 resected patients are alive and eight are relapse free. Three patients died after 11, 12. and 14 months respectively. Toxicity was acceptable: side-effects consisted mainly of grade 11 National Cancer Institute common toxicity criteria (NCICTC) leucopenia and thrombocytopenia in ten patients. Neither treatment-related death nor surgical complications in patients undergoing surgery were observed. This weekly intensive regimen enabled resection in half of previously inoperable tumours with a moderate toxicity. It can be offered to patients with locally advanced unresectable gastric cancer to obtain curative resection.
1993). The use of neoadjuvant chemotherapy is an attractive concept to increase curative resection. A number of trials have tested neoadjux ant chemotherapy. demonstrating that preoperative chemotherapy is feasible and can increase the resection rate (Wilke et al. 1990 : Plukker et al. 1991 . Ajani et al. 1993 : RouDtier et al. 1994 : Kelsen et al. 1996 : Melcher et al. 1996 . Few studies.
Lombroso. 61100 Pesaro. Italy. how ex er. assessed preoperative chemotherapy in patients w ith unresectable gastric cancer at initial surgerx. This approach allow-ed radical surgery in about 40%' of patients with tumours previously unresectable (Wilke et al. 1990 : Plukker et al. 1991 .
In a pilot clinical trial. a wxeekly lowx-dose treatment of 5-fluorouracil .
epidoxorubicin (epiADR). cisplatin (CDDP).
6S-leucovorin. clutathione and bone marrow support w-ith the haematopoietic growth factor filgrastim determined objectixe responses in 25 of 34 advanced gastric cancer patients Nx-ith a mild toxicitx (Cascinu et al. 1993 Glutathione was gixen at a dose of 1.5 m-in 100 ml of normal saline ox er 15 min immediately before each CDDP administration to prevent CDDP-associated neurotoxicity as indicated by our previous experience (Cascinu et al. 1995) . Standard intraxvenous hydration was used: 2 h before initiation of the CDDP infusion. patients were hydrated with 1500 ml of 0.9% sodium chloride to which 20 mequiv. of potassium chloride and 15 mequiv. of magnesium sulphate w ere added. Post-hy dration as continued for 2 h xwith 1000 ml of normal saline solution. (Lightdale. 1992 : Rougier et al. 1994 : Wilke et al. 1994 ). Unfortunately. these procedures are available in only a few centres. However. a reasonably accurate definition of inoperabilitv can also be obtained with traditional techniques. In fact. patients with some characteristics such as: a bulky tumour (>7 cm) or clear signs by CT scan of infiltration of pancreas. aorta. omentum and oesophagus or hepatic extension should not undergo surgerv because it is extremely unlikelv that thev can be completely resected as a CT scan has an accuracy of 80-90%c for the estimation of locoregional extension. and bulkytumours are associated with a high probability of inoperabilitv (Sussman et al. 1988 : Rougier et al. 1994 . On the basis of these considerations. in our study. 16 patients were defined as not resectable after laparotomv. but only as a part of a failed attempt at radical primarv surgery. and 16 patients were defined as not resectable on the basis of endoscopic and CT scan findings.
Accurate objective measure of tumour response to chemotherapy carries the same difficulties as initial assessment. In our patients. after eight weekly chemotherapeutic administrations. tumour assessment was made by-a combination of CT scan and (Findlay et al. 1994 ). This may be responsible for the observed lower activity, as argued by the authors themselves, suggcesting the need for a more prolonged duration of therapy to maximize response to this regimen. Another favourable aspect of our regimen is the mild and acceptable toxicity. We did not observe any surgical complication in the 15 patients who underwent surgery or grade IH-IV NCICTC.
A point of interest arisingr from this w-ork is the relief of abdominal pain and dysphagia in about 60%c of patients complaining, of these symptoms. Although caution is required in the interpretation of these data because a formal assessment of symptom control was not included in this studv. these results seem to support the use of this recrimen as palliative measure also.
In addition, the median survival of resected patients ( 14 months). compared with that Generally reported for unresectable patients (5-6 months). strengthens our belief that this treatment approach should be offered to all patients with locally advanced gastric cancer not amenable to complete surgical resection.
